IPP Bureau
BioMed X launches groundbreaking AI-driven diabetes research in Barbados
By IPP Bureau - January 30, 2026
With its unique combination of AI, population-specific research, and international collaboration, BioMed X’s Barbados project represents a bold new frontier in precision medicine for diabetes and kidney disease
Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience
By IPP Bureau - January 30, 2026
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
Lonza posts CHF 6.5 billion in 2025 sales, marks strong profit growth
By IPP Bureau - January 30, 2026
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
Fides launches imaging CRO focused on early-phase clinical decision-making
By IPP Bureau - January 30, 2026
Fid?s brings core strengths across imaging applications and human biology, supporting work in digestive disease, GI oncology, and select solid tumors
INDIA-EU FTA unlocks access to $572.3 billion EU pharmaceuticals & medical devices market
By IPP Bureau - January 29, 2026
Growth across inorganic & organic chemicals, fertilisers, pharmaceuticals, cosmetics, soaps and detergents
Lubrizol showcases India manufacturing expansion at WHX Dubai
By IPP Bureau - January 29, 2026
The Chennai facility will manufacture high-quality medical tubing for neurovascular and cardiovascular applications, including balloon catheters and other minimally invasive devices
Will Forte joins Teva Pharmaceuticals to shine spotlight on Huntington’s disease
By IPP Bureau - January 29, 2026
HD causes cognitive, behavioral, and physical challenges, including involuntary movements known as HD chorea, which can disrupt daily life
Roche’s investigational obesity drug CT-388 delivers dramatic weight loss in Phase II trial
By IPP Bureau - January 29, 2026
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience
By IPP Bureau - January 29, 2026
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
Bausch Health’s RED-C phase 3 trials fall short, company committed to liver disease research
By IPP Bureau - January 29, 2026
The trials, which enrolled over 1,000 patients across 398 sites in 17 countries, showed that the drug was safe and well-tolerated—but ultimately failed to deliver the hoped-for clinical results
Insilico Medicine’s AI-designed Parkinson’s drug cleared for human trials by FDA
By IPP Bureau - January 29, 2026
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
CitiusTech & Ventra Health unveil AI-powered revenue game-changer
By IPP Bureau - January 29, 2026
The platform uses cutting-edge AI and automation to tackle the entire revenue cycle
Venus Remedies bags second PLI disbursement for FY25, nears full-year incentive
By IPP Bureau - January 29, 2026
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
Eyestem moves closer to blindness breakthrough with phase 2 trial green light
By IPP Bureau - January 29, 2026
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
Cupid gets certification for HIV & Hepatitis B test kits, paving way for global expansion
By IPP Bureau - January 29, 2026
The newly certified kits are designed for early detection and large-scale screening programs
